Skip to main content
Home
language-selector-globe Korea | ko
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe Korea
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • 회사소개 
      • 주요 전략 
      • 직원과 기업문화 
      • 다양성과 포용성 
      • 제품정보  
      • 노바티스그룹 경영진 
      • 핵심 사업부문 
      • 연락처 
      About Novartis Korea 회사소개
    • 환자와 보호자 
      • 환자와 보호자에 대한 노바티스의 약속 
      • 주요 질병 분야 
      • 제품정보  
      • 부작용 보고 
      A couple holding hands 환자와 보호자
    • 의료전문가 
      • 메드허브 
      • 제품정보  
      • 부작용 보고 
      • 혁신 
      • 글로벌 정보서비스 
      Novartis Health Care 의료전문가
    • 혁신 
      • 임상시험 
      • 기술 플랫폼 
      • 데이터와 디지털 
      • 한국노바티스의 혁신 
      • 노바티스의 혁신 
      • 노바티스 생명의학연구소(NIBR) 
      Novartis Innovation 혁신
    • 환경, 사회 및 가브넌스 
      • 윤리 위험 및 규정준수 
      • 의약품 접근성 
      • 환경지속가능성 
      • 글로벌 헬스 
      • 윤리적 행동양식 
      • 한국노바티스의 사회적 책임 
      Novartis ESG 환경, 사회 및 가브넌스
    • 뉴스룸 
      • 보도자료  
      • 이노베이션 스토리  
      • 자료실 
        • 의약품 회수에 관한 공표 
      Novartis News 뉴스룸
    • 인재채용 
      • 채용 공고 
      • 우리가 일하는 방식 
      • 웰빙 
      • 다양성과 포용성  
      • 수상내역 
      Novartis Careers 인재채용
    • Coronavirus 
      multiple coronavirus illustration edit image_1 코로나바이러스감염증-19 (COVID-19) 업데이트
    Seoul Skyline Home
  1. Home
  2. 인재채용
  3. 채용 공고
  • Sort by Sort ascending
  • Job Title
  • Site
  • Location
  • Division
  • Business
  • Functional Area Sort ascending
  • Date Posted
Job Title Site Location Division Business Functional Area Sort ascending Date Posted
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Специалист по системе качества St. Petersburg (City) Russian Fed. Operations Innovative Medicines Quality Sep 15, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Compliance & Quality System Manager Ivrea Italy Operations Innovative Medicines Quality Oct 17, 2024
Quality Control Staff Sasayama Japan Operations Innovative Medicines Quality Oct 18, 2024
Senior Specialist DDIT OPS Mfg Site IT Sasayama Japan Operations CTS Information Technology Jul 22, 2024
Sr. Spec. DDIT IES Supplier Management Hyderabad (Office) India Operations CTS Information Technology Oct 18, 2024
Sr. Spec. IT Solution Delivery INSURGENTES Mexico Operations CTS Information Technology Jul 15, 2024
Manager, Post Production & Video Services Hyderabad (Office) India Corporate Affairs CTS Communications & Public Affairs Oct 04, 2024
Lead - Government Affairs Delhi (Office) India International Innovative Medicines Communications & Public Affairs Oct 15, 2024
Manager, Corporate Marketing Creative & Design East Hanover USA Corporate Affairs CTS Communications & Public Affairs Oct 17, 2024
Director of Global & Swiss Media & Editorial Basel (City) Switzerland Corporate CTS Communications & Public Affairs Oct 18, 2024
Manager, Digital Storytelling Remote Position (USA) USA Corporate Affairs CTS Communications & Public Affairs Oct 18, 2024
Public Affairs Manager (m/f/d) Berlin West (Non-Sales Force) (Novartis Pharma GmbH) Germany International Innovative Medicines Communications & Public Affairs Jul 09, 2024
Patient Engagement Lead İstanbul Kavacık Turkey Corporate Affairs CTS Communications & Public Affairs Sep 03, 2024
EA & Program Coordinator Beijing (Beijing) China Corporate Affairs Innovative Medicines Communications & Public Affairs Sep 03, 2024
Government Affairs Manager Moscow (City) Russian Fed. Corporate Affairs Innovative Medicines Communications & Public Affairs Jul 29, 2024
Communication & Patient Advocacy Manager (f/m/d) Vienna Austria International CTS Communications & Public Affairs Sep 24, 2024
Public Affairs Manager Ankara Gimat Turkey International Innovative Medicines Communications & Public Affairs Sep 13, 2024
Executive Director, Public Affairs LaCan Region East Hanover USA Corporate Affairs Corporate Communications & Public Affairs May 09, 2024
Associate Director, R&D Portfolio and Engagement - Communications Cambridge (Massachusetts) USA Corporate Affairs CTS Communications & Public Affairs Oct 08, 2024
Associate Director, Finance and Strategy & Growth Activation Communications East Hanover USA Corporate Affairs CTS Communications & Public Affairs Oct 08, 2024
Comms & Engagement Manager Amsterdam Netherlands Corporate Affairs CTS Communications & Public Affairs Oct 16, 2024
Executive Director, Therapy Area Communications and Patient Advocacy Basel (City) Switzerland Corporate Affairs CTS Communications & Public Affairs Oct 16, 2024
Associate Director, Corporate Event Marketing Cambridge (USA) USA Corporate Affairs CTS Communications & Public Affairs Oct 16, 2024
Vice President of European Public Affairs Vilvoorde Belgium Corporate Affairs Innovative Medicines Communications & Public Affairs Oct 10, 2024

Pagination

  • ‹ Previous page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42

한국노바티스

Navigate Novartis
  • 회사소개
  • 환자와 보호자
  • 의료전문가
  • 혁신
  • 환경, 사회 및 가브넌스
  • 뉴스룸
  • 인재채용
Media Center
  • 보도자료
  • 이노베이션 스토리
Other Novartis Websites in Korea
  • MedHub
  • Novartis Global
  • 한국노바티스 LinkedIn
  • 한국노바티스 YouTube
Footer Bottom
© 2024 Novartis AG
  • 개인정보 처리방침
  • 이용약관
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
이 사이트는 국내 거주자들을 위한 사이트입니다. KR2205234431